BR0314383A - Compostos de oxazol e tiazol como inibidores do fator de crescimento transformante(tgf) - Google Patents

Compostos de oxazol e tiazol como inibidores do fator de crescimento transformante(tgf)

Info

Publication number
BR0314383A
BR0314383A BR0314383-0A BR0314383A BR0314383A BR 0314383 A BR0314383 A BR 0314383A BR 0314383 A BR0314383 A BR 0314383A BR 0314383 A BR0314383 A BR 0314383A
Authority
BR
Brazil
Prior art keywords
tgf
oxazole
growth factor
transforming growth
inhibitors
Prior art date
Application number
BR0314383-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Laura Cook Blumberg
Michael John Munchhof
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0314383A publication Critical patent/BR0314383A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR0314383-0A 2002-09-18 2003-09-08 Compostos de oxazol e tiazol como inibidores do fator de crescimento transformante(tgf) BR0314383A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41212002P 2002-09-18 2002-09-18
US47126503P 2003-05-16 2003-05-16
US48458103P 2003-07-02 2003-07-02
PCT/IB2003/003823 WO2004026863A1 (en) 2002-09-18 2003-09-08 Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors

Publications (1)

Publication Number Publication Date
BR0314383A true BR0314383A (pt) 2005-07-19

Family

ID=32034216

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314383-0A BR0314383A (pt) 2002-09-18 2003-09-08 Compostos de oxazol e tiazol como inibidores do fator de crescimento transformante(tgf)

Country Status (28)

Country Link
US (1) US7273936B2 (enExample)
EP (1) EP1542994B1 (enExample)
JP (1) JP4518956B2 (enExample)
KR (1) KR20050057415A (enExample)
CN (1) CN1681810A (enExample)
AP (1) AP2005003261A0 (enExample)
AR (1) AR041273A1 (enExample)
AT (1) ATE430147T1 (enExample)
AU (1) AU2003256003A1 (enExample)
BR (1) BR0314383A (enExample)
CA (1) CA2499429C (enExample)
CO (1) CO5550473A2 (enExample)
CR (1) CR7743A (enExample)
DE (1) DE60327443D1 (enExample)
EA (1) EA200500354A1 (enExample)
ES (1) ES2323421T3 (enExample)
HR (1) HRP20050250A2 (enExample)
IS (1) IS7711A (enExample)
MA (1) MA27443A1 (enExample)
MX (1) MXPA05002332A (enExample)
NO (1) NO20051838L (enExample)
OA (1) OA12926A (enExample)
PA (1) PA8582701A1 (enExample)
PE (1) PE20040987A1 (enExample)
PL (1) PL375975A1 (enExample)
TW (1) TW200413362A (enExample)
UY (1) UY27978A1 (enExample)
WO (1) WO2004026863A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
WO2004026306A2 (en) * 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
CN1681805A (zh) * 2002-09-18 2005-10-12 辉瑞产品公司 作为转化生长因子(tgf)抑制剂的新的咪唑类化合物
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0313914D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
BRPI0515012A (pt) * 2004-08-13 2008-07-01 Genentech Inc substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
US20070275968A1 (en) * 2004-09-07 2007-11-29 Hitoshi Kurata Substituted Biphenyl Derivative
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
CN101330914A (zh) * 2005-12-16 2008-12-24 爱尔康公司 使用alk5调节剂控制眼内压
EP2154965A4 (en) * 2007-05-29 2011-08-17 Glaxosmithkline Llc NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS
US8268874B2 (en) 2008-03-03 2012-09-18 University Of Notre Dame Du Lac Anti-cancer compounds, synthesis thereof, and methods of using same
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
AU2012203026B2 (en) * 2008-03-21 2014-06-12 Novartis Ag Novel heterocyclic compounds and uses thereof
EP2300466B1 (en) 2008-06-20 2014-08-06 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
PL3089971T3 (pl) 2014-01-01 2021-01-25 Medivation Technologies Llc Związki i sposoby ich zastosowania
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN105585565B (zh) * 2014-10-23 2019-10-01 中国医学科学院药物研究所 含2-苯胺基-4-噻唑基吡啶衍生物及其制法和药物组合物与用途
CN106243012A (zh) * 2016-08-02 2016-12-21 北方民族大学 新型吲哚类衍生物及其制备方法
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
CN110831593A (zh) * 2017-06-14 2020-02-21 特维娜有限公司 用于调节s1p1活性的化合物及其使用方法
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
CN112694477B (zh) * 2019-10-22 2024-02-06 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物,包含其的药物组合物,其制备方法及其用途
MX2022005766A (es) 2019-11-19 2022-08-08 Trevena Inc Compuestos y métodos para la preparación de compuestos moduladores de esfingosina 1-fosfato tipo 1 (s1p1).
CN115466260B (zh) * 2022-09-06 2023-10-13 延边大学 含氨基酸结构的咪唑和噻唑类衍生物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0149884B1 (en) 1983-09-09 1992-12-16 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-thiazole derivatives, their production and use
GB9201692D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6087381A (en) 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
US5932576A (en) 1997-05-22 1999-08-03 G. D. Searle & Company 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
JPH11193281A (ja) 1997-10-27 1999-07-21 Takeda Chem Ind Ltd アデノシンa3受容体拮抗剤およびチアゾール化合物
AU4798000A (en) * 1999-04-09 2000-11-14 Smithkline Beecham Corporation Triarylimidazoles
EP1205478A4 (en) 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd P38MAP KINASE INHIBITORS
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
EP1349851A4 (en) 2000-11-16 2004-09-08 Smithkline Beecham Corp COMPOUNDS
GB0027987D0 (en) * 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
WO2002051442A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Concomitant drugs
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
ATE291020T1 (de) 2001-02-02 2005-04-15 Smithkline Beecham Corp Pyrazolderivate gegen tgf überexprimierung
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
JPWO2002062775A1 (ja) 2001-02-02 2004-06-10 山之内製薬株式会社 2−アシルアミノチアゾール誘導体又はその塩
WO2002062787A1 (en) 2001-02-02 2002-08-15 Glaxo Group Limited Pyrazoles as tgf inhibitors
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
EP1402900A1 (en) 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Medicinal compositions
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1539748A1 (en) 2002-07-31 2005-06-15 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
GB0217787D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd C ompounds
WO2004026306A2 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
CN1681805A (zh) 2002-09-18 2005-10-12 辉瑞产品公司 作为转化生长因子(tgf)抑制剂的新的咪唑类化合物
JP2006502236A (ja) 2002-09-18 2006-01-19 ファイザー・プロダクツ・インク 形質転換成長因子(tgf)阻害剤としてのトリアゾール誘導体
KR20050057441A (ko) 2002-09-18 2005-06-16 화이자 프로덕츠 인코포레이티드 전환 성장 인자 억제제로서의 신규한 아이소티아졸 및아이속사졸 화합물

Also Published As

Publication number Publication date
MA27443A1 (fr) 2005-07-01
CR7743A (es) 2005-06-15
CO5550473A2 (es) 2005-08-31
ATE430147T1 (de) 2009-05-15
JP2006502235A (ja) 2006-01-19
JP4518956B2 (ja) 2010-08-04
HRP20050250A2 (en) 2005-10-31
AU2003256003A1 (en) 2004-04-08
KR20050057415A (ko) 2005-06-16
WO2004026863A8 (en) 2005-04-21
US7273936B2 (en) 2007-09-25
IS7711A (is) 2005-02-24
DE60327443D1 (de) 2009-06-10
US20040110797A1 (en) 2004-06-10
EP1542994A1 (en) 2005-06-22
CA2499429A1 (en) 2004-04-01
ES2323421T3 (es) 2009-07-15
WO2004026863A1 (en) 2004-04-01
AP2005003261A0 (en) 2005-03-31
PA8582701A1 (es) 2004-04-23
CA2499429C (en) 2010-09-21
EP1542994B1 (en) 2009-04-29
CN1681810A (zh) 2005-10-12
NO20051838L (no) 2005-04-15
MXPA05002332A (es) 2005-06-08
UY27978A1 (es) 2004-04-30
AR041273A1 (es) 2005-05-11
OA12926A (en) 2006-10-13
TW200413362A (en) 2004-08-01
PL375975A1 (en) 2005-12-12
EA200500354A1 (ru) 2005-10-27
PE20040987A1 (es) 2004-12-27

Similar Documents

Publication Publication Date Title
BR0314372A (pt) Compostos imidazol como inibidores do fator de crescimento tranformador (tgf)
BR0314286A (pt) Compostos de isotiazol e isoxazol como inibidores do fator de crescimento transformante (tgf)
WO2004026863A8 (en) Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
BRPI0407999A (pt) compostos heteroaromáticos fundidos como inibidores do fator de transformação do crescimento (tgf)
BR0314302A (pt) Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf)
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
PA8583401A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
SE0202539D0 (sv) Compounds
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
NO20085077L (no) Nye forbindelser
SE0103836D0 (sv) Novel compounds
SE0104140D0 (sv) Novel Compounds
SE9904505D0 (sv) Novel compounds
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
BR0215312A (pt) Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0409427A (pt) composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
ATE316083T1 (de) Adamantanderivate
NO20082445L (no) Neuropeptid-2 reseptor-agonister
SE0300480D0 (sv) Novel compounds
UA83691C2 (ru) Применение замещенных 2-аминотетралинов для упреждающего лечения болезни паркинсона
CY1111256T1 (el) Παραγωγα αζαδικυκλοοκταν-3-ονης και χρηση τους
BRPI0411503A (pt) composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto
BRPI0407055A (pt) Derivados de isotiazol
SE9902765D0 (sv) Novel compounds

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2166 DE 10/07/2012.